Ahead Therapeutics is continuously seeking new partnerships to expand our reach and capabilities. We maintain a lean organizational structure, with key activities such as liposome development and synthesis for pre-clinical assays managed in-house.
Simultaneously, we leverage our extensive network to foster lasting, trusted collaborations with leading specialists in various fields, ensuring the highest standards in scientific and technical development.
“IGTP advises Ahead Therapeutics on scientific matters and offers its facilities for in vitro and in vivo assays as well as advising its clinicians.”
“ICN2 advises Ahead Therapeutics on technical matters for liposome synthesis. Ahead has been using its facilities for manufacture of the liposomes needed for the pre-clinical phase”
“IRB Lleida is the facility where Ahead conducts several in vivo assays involving NOD mice for Type 1 Diabetes, along with various other in vitro assays. The group is led by Dr. Joan Verdaguer.”
“VHIR-CEMCAT is the center where certain in vivo assays employing EAE mouse models for Multiple Sclerosis (MS) are conducted. Led by Dr. Carmen Espejo, the group has over 15 years of experience with this animal model, positioning them as one of the leading MS research groups in our country”
“The University of Barcelona collaborates with Ahead by handling all analytical tasks, including analytical method development for product characterization and quality control, within the laboratory of the Analytical Chemistry Department.”
“Sant Pau Hospital is the reference hospital centre for the trial of our leading asset, Myasthenia Gravis. We collaborate closely with Dr. Elena Cortés to plan the Clinical Trial, with a dedicated team member performing all the in vivo assays for Myasthenia Gravis. “
“ZBM Patents collaborates with us in managing and formulating the IP strategy. Additionally, ZBM Business Connect has significantly contributed to the establishment of Ahead Therapeutics and stands as one of our primary stakeholders.”
“Innoqua Toxicology collaborates with Ahead in defining the strategy for the pre-clinical regulatory phase. Additionally, it will assist in preparing scientific advisory meetings with regulatory agencies and provide support for IND filing.”
“Asphalion collaborates with Ahead to define the regulatory strategy for the CMC (Chemical Manufacturing & Control) pre-clinical regulatory phase. Additionally, it will facilitate the preparation of scientific advisory meetings with regulatory agencies and provide support for IND filing.”
“Ecopol Tech collaborates with us by leasing a cleanroom (ISO 7 & 8) and an organic chemistry lab. In these facilities, we develop and optimize manufacturing processes, refine formulations, and conduct routine parenteral batch production, all within a controlled, high-quality environment.”
“The Catalan Finance Institute (ICF) is assisting Ahead’s growth by providing financial backing, supporting the development of our new therapy through a long-term loan.”
Partners are essential for biotech companies; without adequate financial backing, progress becomes unfeasible. Therefore, since our inception, we have developed an extensive network with investors to ensure the realization of our goals. At each stage of development, we carefully align with the appropriate investor types: Friends, Family, and Fools (FFF), Business Angels (BA), Family Offices (FO), and Venture Capitalists (VCs).
Additionally, strategic leveraging of the company is of paramount importance for us. We actively pursue funding opportunities through various public calls for research projects with national and international institutions such as CDTI, ENISA, H2020, and ICF.
Our initial financing round successfully concluded in December 2017, and since then, we have made significant strides in advancing our mission and expanding our operations. We are now in the midst of raising our Series A funding, which will be crucial for us to initiate our clinical trials and further scale our efforts.If you are exploring investment opportunities in innovative ventures with strong potential, we would be delighted to discuss how you can be part of our exciting journey. Contact us.
Ahead Therapeutics adopts a balanced pipeline development strategy that combines two complementary approaches:
a) in-house development to maximize asset value and
b) co-development or early licensing partnerships to mitigate scientific and financial risks.
Ahead Therapeutics is committed to advancing the worldwide effort in preventing, caring, and curing Autoimmune Diseases. All our efforts are focused on developing a therapeutic approach aimed at genuine cures rather than merely chronic palliative treatments. We strongly believe that partnering with Patient Advocacy Groups and/or Research Foundations will accelerate scientific progress, ultimately making life easier, safer, and healthier for patients with Autoimmune Diseases.
